Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
Cosmo Pharmaceuticals N.V. reports news across its life sciences business, including MedTech AI, dermatology, gastrointestinal disease programs, and contract development and manufacturing. Company updates frequently cover the GI Genius™ platform and real-time medical AI for endoscopy, dermatology assets such as Clascoterone 5% topical solution and Winlevi®, and gastroenterology research programs in bile acid diarrhea and distal ulcerative colitis.
Recurring disclosures also include annual results, recurring revenue trends, dividend actions, AGM voting outcomes, ESG reporting, board and remuneration matters, and capital-structure authorizations. Partnership and R&D collaboration announcements describe how Cosmo extends AI-enabled medical technology into additional clinical applications while maintaining a broader portfolio of pharmaceutical and CDMO activities.
Cosmo Pharmaceuticals (OTC:CMOPF), a leader in AI-powered healthcare and specialty pharma, reported strong H1 2025 results and raised its EBITDA guidance by €4.5 million. The company achieved total revenues of €51.7 million, including €41.9 million in recurring revenues.
Key growth drivers include GI Genius™ recurring revenues up 128% YoY and Winlevi® recurring revenues up 23% YoY. The company maintains a strong financial position with €133.3 million in cash and investments. Updated FY2025 guidance projects total revenues of €102-107 million and EBITDA of €5.5-7.5 million.
Operating expenses were controlled with R&D at €18.0 million (-6% YoY) and SG&A at €14.3 million (-13% YoY). The company operates across four strategic platforms: AI-powered MedTech, Dermatology, GI innovation, and CDMO services.
Cosmo Pharmaceuticals (OTC:CMOPF) has launched Winlevi® (clascoterone) cream 1% in Singapore and Malaysia through its partnership with Hyphens Pharma, marking its first entry into Southeast Asia. Winlevi® is the first topical androgen receptor inhibitor for acne treatment in over 40 years, approved for patients aged 12 and older.
The treatment demonstrated superior efficacy in two Phase III studies, showing significant improvements in both non-inflammatory and inflammatory lesion counts. Hyphens Pharma has in-licensed the product for distribution across ten Southeast Asian countries, with progressive rollout planned for other markets in the region.
This launch aligns with Cosmo's 2030 vision for sustainable revenue growth through geographic expansion, addressing a market where acne affects over 90% of the population at some point in their lives.
Cosmo Pharmaceuticals (OTC:CMOPF), a global AI-powered healthcare and specialty pharma company, has announced significant progress in its ESG initiatives. The company achieved an MSCI ESG rating upgrade from "BBB" to "A" and saw its LSEG ESG score double to 62.98, ranking #42 globally among peers.
Key developments include becoming a signatory to the UN Global Compact and committing to the Science Based Targets initiative (SBTi) for emissions reduction. These achievements align with Cosmo's Vision 2030 strategy, positioning the company to attract investments from ESG-focused funds, particularly those aligned with SFDR Articles 8 and 9.
Cosmo N.V. (SIX: COPN) unveiled its ambitious 2030 vision and strategic roadmap during its Investor Day 2025 in Zurich. The company aims to achieve €480 million in recurring revenues by 2030, representing a five-year CAGR of 39%, with €260 million expected from core business and €220 million from late-stage assets and Digital AI platforms.
The company targets an EBITDA of €195 million by 2030, representing a 40% margin. The core business growth (23% CAGR) will be driven by the expansion of GI Genius™ platform, global adoption of Winlevi®, and stable growth from Gastroenterology and CDMO businesses.
The Investor Day event featured presentations on the company's strategic roadmap across Medtech AI, Dermatology, Gastro, and CDMO franchises, along with insights from KOLs and technology demonstrations. Cosmo also revealed its refreshed corporate identity, positioning itself as a digitally native, patient-impact-focused company.
Cosmo (OTC:CMOPF) has announced the sale of its "Digital Trust" business to Tinexta InfoCert for €8.3 million. The transaction, expected to close by end of June 2025, involves the divestment of digital security services focused on identity protection and process dematerialization for healthcare organizations.
This strategic move is part of Cosmo's portfolio streamlining initiative, allowing the company to focus on core business areas including AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services. The company aims to strengthen its position as a focused, innovation-driven healthcare organization with global reach.
Cosmo Pharmaceuticals (OTC:CMOPF) has announced a groundbreaking clinical study integrating their GI Genius™ AI endoscopy module with Apple Vision Pro, set to begin in July 2025 at Rush University Medical Center. The first-of-its-kind usability study will evaluate a new software application that enables physicians to view AI-generated insights during live colonoscopy procedures through Apple Vision Pro.
The GI Genius™ system has demonstrated the ability to increase adenoma detection rates by 14.4%. The study results will support Cosmo's upcoming FDA submission. The technology is commercially distributed globally through Cosmo's partnership with Medtronic, their exclusive distributor since 2019.
Cosmo (CMOPF) is participating in Digestive Disease Week® (DDW) 2025 in San Diego, California from May 3-6. The company's leadership team is conducting strategic meetings with key opinion leaders, innovators, and potential partners in AI and gastrointestinal (GI) drug development. DDW, attracting over 13,000 gastroenterologists, researchers, and industry leaders annually, serves as a platform for Cosmo to advance its position in AI-powered endoscopy and GI therapeutics.
CEO Giovanni Di Napoli emphasized DDW's importance as the epicenter of GI innovation. The company has also convened its AI Advisory Board at the event to guide strategic priorities and accelerate development across its AI platform. Cosmo's participation demonstrates its commitment to advancing GI care through technology integration and strategic partnerships.
Cosmo Pharmaceuticals has maintained its 2025 financial guidance despite receiving a negative CHMP opinion for Winlevi® (clascoterone cream 1%) in Europe. The company expressed disappointment but emphasized that this development will not materially impact their financial expectations for the year.
Key points:
- Company remains confident in Winlevi's clinical profile
- Management sees Winlevi as addressing an important unmet need in dermatology
- Team is preparing a re-examination submission
- Commitment to securing European patient access remains strong
The company will continue to provide updates throughout the re-examination process, maintaining transparency with stakeholders.